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SP-0519   
Errors and uncertainties in DIR-based accumulated dose 
J. Siebers1 
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The enabling technology for dose mapping, treatment evaluation and 
adaptation based upon cumulative dose is deformable image 
registration (DIR).  Ideally, DIR creates an exact correspondence 
between tissue sub-volumes in the co-registered images.  
Realistically, DIR creates an approximate map of image content (e.g. 
grey-scales, landmarks, contours) between two images.  As a result, 
current DIR algorithms yield an imperfect correspondence between 
tissue elements for both intra- and inter-fraction registration.  Since 
tissue response is a function of the accumulated and per fraction dose 
to each sub-volume, registration errors add uncertainty to patient 
dose evaluation.  Unfortunately, necessary and sufficient methods do 
not exist for automated patient DIR validation; however, several 
necessary but insufficient methods do exist.  This presentation will (1) 
describe the use of inverse mapping consistency and unbalanced 
energy to detect DIR errors; (2) probe the correspondence of these 
metrics with dose mapping errors and cumulative dose uncertainty; 
(2) explain a 3D distance-to-difference (DTD) metric which can be 
used to determine DIR error tolerances sufficient to keep dose 
mapping errors below a user-specified threshold; (3) demonstrate the 
necessity for self-consistent registrations in adaptive treatment 
protocols paradigms in which accumulated dose is projected on to the 
anatomy of the day; (4) illustrate methods to evaluate random 
registration uncertainties and the corresponding dose uncertainties; 
and (5) look at the impact of correlated registration errors on patient 
dose distributions.  Even though DIR and dose mapping is imperfect, it 
can be clinically beneficial if it improves the estimate of the 
accumulated patient dose.  Users must be keenly aware of potential 
errors and their consequences. 
   
 LOOK INSIDE: TREATMENT REPRODUCIBILITY: WHERE 
IMAGING CANNOT REPRESENT THE REALITY  
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3D imaging represents a snapshot in time of the patient anatomy. By 
use of 4D imaging, either as imaging of the respiration cycle or as 
consecutive 3D images over thetreatment course, dynamics of the 
anatomy can be measured and included in the treatment planning 
process. However, due to the added information/complexity by use of 
4D techniques relative to 3D imaging there can be some hesitations 
implementing 4D imaging clinically. 
The intent of using 4D imaging can be numerous. Currently, the main 
purpose of CBCT imaging is to ensure the correct treatment position 
of the patient. Use of 4D CBCT can ensure that the tumour is imaged 
with less image artefacts and with the tumour in an average position. 
This can reduce the treated volume significantly.   
However, 4D imaging can also be used to e.g. monitor changes of the 
volume of a lung tumour over the treatment course. Studies 
correlating tumour volume changes to clinical outcome are starting to 
appear. Based on such a correlation it might be possible to adapt the 
treatment to the specific patient e.g. as an accelerated treatment. 
Similarly there are also studies which investigate the possibility to use 
CBCT as a way to predict expected toxicity. 
CBCT imaging can also potentially be used for recalculation of the 
treatment dose. For standard CBCT a unique link between electron 
density and CBCT value does not exist. This prevents calculation of 
dose which includes correction for density variations within the 
patient. The cause of the problem is scattered dose reaching the 
detector. The expected scatter contribution can be corrected by use 
of Monte Carlo techniques which is feasible today on small computer 
clusters within clinically relevant times. 
The above use of 4D imaging requires different degree of image 
quality. Since image quality is related to imaging dose and time the 
specific goal of the imaging needs to be defined in order to get the 
maximum benefit of 4D CBCT. Having considered the imaging goal a 
number of practical issues related to the use of 4D CBCT appear e.g. 
which respiration phase should be used in validating patient position, 
which respiration phase should be used for treatment calculation, 
what if mediastinal nodes and lung tumour do not move 
synchronously, how to optimise workflow and minimise imaging dose, 
and what education is needed to evaluate the additional information. 
Conclusion: 4D CBCT has been available for a number of years and has 
the potential not only to optimise the treatment position of the 
patient, but also to measure patient specific response to the delivered 
treatment. In implementation of 4D imaging it is obviously important 
to realise the main goal of the imaging, but also to realise that the 
additional acquired information adds a number of practical issues and 
that additional education of treatment staff is necessary in order to 
maximise the benefit of the imaging. 
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Respiratory management can provide a potential for increasing 
positional precision, which can facilitate dose escalation with 
maintained healthy tissue toxicity.Respiratory management can 
include breath-holding, beam gating or tumour tracking during 
irradiation. However, performing such manoeuvres in a safe manner is 
not trivial, although the technical capabilities are to a large extent 
available. It has been shown that huge variations in respiratory 
pattern can be present both intra- and inter-fraction, and that 
correlation between respiratory surrogates and actual tumour motion 
may not be consistent from session to session. Target localisation 
through respiratory monitoring and correlation must therefore be 
performed in a consistent manner during treatment preparation, and 
for each instance of treatment delivery.  
There are basically two challenges related to target localisation 
adequate for respiratory management; achieving target visibility and 
achieving representative positional information. Both of these 
challenges are most easily met by using more complex imaging 
methods over longer duration of time.However, there may on the 
other hand be motivation for limiting the amount and complexity of 
imaging, related to availability, work-flow, risk management and cost-
effectiveness.  
This presentation goes through some specific examples exhibiting 
target localisation challenges, and solutions for balancing complexity 
and amount of imaging with these other factors. 
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In radiation therapy, intra-fraction motion results in significant 
geometric and dosimetric uncertainties in the therapeutic dose 
delivery treating thoracic and abdominal tumors. Technological 
evolution has brought new possibilities into the field which enable 
active dynamic compensation of intra-fraction movements of the 
tumor, limiting the volume of surrounding tissue exposed to high 
doses. Real-time tumor tracking (RTTT) is a fairly recent motion 
compensation technique, which involves a complex workflow. The 
currently available linac systems supporting this technique all use a 
so-called hybrid approach to locate the moving tumor during tracking. 
In a preparatory step, repeated X-ray images are acquired together 
with a synchronized acquisition of the breathing signal from the 
patient skin movement. A dedicated mathematical model is optimized 
to fit the correlation between external breathing signal and internal 
tumor motion. The motion compensation is driven by the external 
signal and the model. This allows reduction of additional imaging dose 
and can be used to introduce some robustness to irregular breathing. 
However it does also introduce some residual tracking error due to 
suboptimal fit and the correlation model prediction accuracy has a 
limited validity in time due to possible systematic drifts in the 
breathing pattern and movement of the patient. As such the 
performance of these RTTT solutions is dependent on the correlation 
model but also on the time efficiency, to minimize possible drifting. 
The pre-treatment imaging, the treatment planning process and PTV 
volume definition should incorporate the dynamic nature of the RTTT 
process with 4D CT imaging and dose accumulation. In terms of quality 
assurance (QA), also for tumor tracking, the amount  of patient 
specific QA and the machine related QA should be balanced. Moving 
phantom experiments can be performed in combination with various 
dosimetry techniques. However, RTTT is a type of radiotherapy 
treatment adaptation which involves a continuous interaction 
between a technical system and the patient. As such, part of the 
commissioning of such a system and also routine patient specific QA 
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should involve an assessment of this interaction, which can only 
partially be simulated with phantoms. The dynamic and even more 
importantly the automatic real-time adaptive nature of the tumor 
tracking process add some additional requirements to the QA process. 
Acquisition of intrafraction imaging in combination with logging of 
dynamic machine parameters during treatment allow a detailed 
quantification of the tracking performance at all times during 
treatment delivery. An overview is given of the RTTT process with the 
Vero gimbaled linac system in clinical practice. 
 
 SYMPOSIUM: THE ESTRO YOUNG TASK FORCE: WHAT 
IT IS, HOW IT WORKS AND WHAT IT CAN DO FOR 
YOUNG MEMBERS.  
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There is an increasing participation, involvement and visibility of 
young members in ESTRO over the last years with the development of 
pedagogical and research activities, structures and tools targeted to 
young members and often conducted by young members but open to 
all ESTRO members.  
In 2007 a young scientific committee was created to orgasine a young 
ESTRO track for ESTRO27 meeting in Göteborg. Since then young 
ESTRO session (for all four disciplines in radiation oncology) has been 
part of each ESTRO annual meeting and each ESTRO forum expending 
to a full day track since the London ESTRO aniversary meeting in 2011. 
In late 2009 the young corner in the ESTRO newsletter was created to 
provide an additional communication tool between society members 
and more specifically between young members. Since 2010 each 
standing committee has at least one young representative who is 
considered as a liaison person between his committee and young 
members (through the young scientific committee and/or the editorial 
team of the young corner). 
The first young task force was created following the young session at 
the ESTRO aniversary meeting. This task force has proposed a 
roadmap for the development of young members integration in the 
society approved and signed by the president of ESTRO and the chair 
of this young task force at ESTRO31 in 2012 [1]. This roadmap states 5 
key points: setup a young strategy meeting, develop young activities 
in ESTRO, support young professionals in their scientific activities, 
promote educacional activities, provide better access for young to 
ESTRO services. 
This comes in agreement with the ESTRO vision published after the 
2012 ESTRO strategy meeting where young representatives were 
invited as well [2]. This document recognises ”the strategic 
importance of young members to the development and future of 
ESTRO and the clinical discipline of radiation oncology” and confirms 
that the ESTRO board commits to ”prioritise initiatives to increase 
young member participation in the society”. 
One of the key points of the roadmap was already achieved through 
the young strategic meeting organised in Taormina in october 2012. 
This has lead to a list of priorities with an action plan. Further 
achievments will be delivered in the second ESTRO forum in Geneva in 
2013 together with a roadmap for the futur young task force leading 




2. Valentini V, Bourhis J, Hollywood D. ESTRO 2012 strategy 
meeting: vision forradiation oncology. 
RadiotherOncol. 2012Apr;103(1):99-102 
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Activities 2012-2013 and report from the AGORA meeting 
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The first young task force was formed at the Anniversary meeting in 
London in 2011 under the impulsion of President Jean Bourhis and 
President elect Vincenzo Valentini. The aim was to settle a group of 
young persons involved in ESTRO or recruited outside of ESTRO to 
implement concrete advances for young people. The ESTRO President 
chairs the task force and the task force is partly renewed every year. 
Its first mission was to conduct a survey to better understand the 
needs of young members from all over Europe. This task force 
finalized its work at the ESTRO 31 in Barcelona with the signing of a 
roadmap, an agreement between young ESTRO members and ESTRO 
president showing the deep commitment of ESTRO board towards the 
expectations of young people in the field of radiation oncology and 
the road to follow in the near future. 
The new task force has had the objective to transform the roadmap 
into actions leading to a contract that will be signed at the 2nd ESTRO 
Forum in Geneva in 2013. One of the first points ofthe roadmap was to 
conduct a strategy meeting for young people, in order to discuss key 
challenges in the field of radiation oncology. This retreat took place in 
Taormina, Sicily, in October 2012 and was the occasion of fruitful 
exchanges between young people (physicists, radiation 
oncologists,radiobiologists and RTTs) from all over Europe and 
distinguished members of the ESTRO board, including the three 
Presidents, the Green Journal’s editor in chief and the chairman of 
the Education committee. Major topics included educational services, 
scientific exchange, professional/membership issues and young 
member’s society structures. It ended with a session devoted to the 
implementationof new activities for young members. 
The young ESTRO task force is now facing great and exciting 
challenges. Bringing up new ideas is good, but helping and making 
them become true is even better. Improving education, clinical or 
scientific exchange, networking or web-based services are some of the 
ongoing projects where the young task force is involved. This is the 
real goal of the previous young task forces, and of the coming ones. 
The major priorities defined by the young Task Force and the ESTRO 
board will be presented during the session. 
If you are interested, come to the session, and you will see what 
ESTRO can do for young people, but also how young people can help 
improving ESTRO services. 
   
SP-0525   
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This session marks the finalization of the 2nd Young Task Force (YTF), 
a concept created following prolific discussions during and following 
the ESTRO 30 year anniversary conference in 2011. The YTF is an 
instrument designed for a dynamic and efficient interaction between 
the core management structures of ESTRO and the youngest members 
of the society.  This is achieved by appointing the members of the YTF 
on an annual basis, with a mission to work along a roadmap defined by 
the previous task force.   
The current YTF has focused on identifying and exploring the different 
needs and aspirations of young RT scientists / ESTRO members within 
the different domains of ESTROs core activities. At the time of 
writing, the different ideas put forward are being evaluated, and the 
details of this will form the backbone of the mission for the next YTF. 
Overall, the new activities proposed for the next YTF will complement 
the existing activities for and by young ESTRO members (e.g., 
conference activities, newsletter and general information activities) 
and will also be seen as an integral part of the general development 
of the society. During this session the final details of this process will 
be described and the roadmap for the next YTF will be signed by the 
president of the society.   
   
 POSTER DISCUSSION: 13: CLINICAL: CNS/ HEMATOL-
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Purpose/Objective: Second primary cancers (SPC) are among the 
possible late toxicities in Hodgkin’s lymphoma (HL) survivors. The 
extent of radiation fields and high doses are counted among probable 
aetiological causes. We reviewed long term results of a mono-
institutional, randomized trial comparing sub-total nodal irradiation 
(STNI) versus involved-field irradiation (IFRT) after a short-course of 
